InFlectis BioScience Completes Enrollment of Its Phase 2 Trial of IFB-088 for the Treatment of Amyotrophic Lateral Sclerosis; Anticipates Initial Results Later This Year
31 Jan 2024
Phase 2
Nantes, France--(News - January 31, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2 clinical trial of IFB-088 (INN: icerguastat), a novel investigational treatment of Amyotrophic Lateral Sclerosis (ALS).
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
InFlectis completed enrollment in its Phase 2 clinical trial of IFB-088 in ALS.
IFB-088 is capable of crossing the blood-brain barrier and believed to act by selectively inhibiting a biomolecular switch to give cells additional time to repair or eliminate mis-folded proteins.
Initial findings to be reported as early as the end of 2024.
Click image above to view full announcement.
About InFlectis BioScience
InFlectis is a French-based drug discovery company developing first-in-class therapies for neuromuscular diseases. We are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS and CMT, a rare and progressive hereditary nerve condition.
Contacts:
Philippe Gu'edat
philippeguedat@inflectisbioscience.com
Source: Inflectis
To view the source version of this press release, please visit
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.